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Introduction
Novel interventions are needed for the treatment of
women with metastatic ovarian cancer that causes 14,000
deaths each year in the USA. Retrospective analysis of
tumor infiltrating lymphocytes (TIL) infused into patients
who achieved complete, durable regressions of metastatic
melanoma revealed that the responses were likely
mediated through recognition of somatic non-synonymous
mutations. Furthermore, prospective administration of
mutation-specific TIL resulted in an ongoing partial
response in a patient with cholangiocarcinoma.
Methods
We now studied whether TIL obtained from metastatic
ovarian cancer recognized tumor mutations. Exome and
transcriptome sequencing was performed from resected
metastatic ovarian cancer deposits in parallel with growth
of TIL fragment cultures in IL-2. Long peptides and tan-
dem minigenes (TMGs) encompassing all mutations were
synthesized, introduced into autologous antigen presenting
cells, co-cultured with individual TIL fragments and T cell
reactivity was determined by interferon-g ELISPOT and
surface expression of 41BB.
Results
In patient 4046 (280 mutations), 8 of 24 fragments were
reactive to TMG15 (86.9% ± 1.5% 41BB+ T cells; mean
± SEM). Co-culture with individual long peptides corre-
sponding to the mutations in TMG15 revealed that the
T cells recognized the USP9XY373C mutation, a putative
tumor suppressor gene on the X chromosome. Two of
14 fragments from patient 4067 (122 mutations) were
responsive to autologous tumor and a cumulative 41BB+
expression was observed at 51% and 8% in CD4+ and
CD8+ T cells, respectively, following co-culture with
TMG2, TMG5, TMG6 and TMG7. Using UV-exchange-
able peptide tetramers, the following candidate minimal
epitopes from this patient were identified: ZWILCHS296F
from TMG2, SPINT2H35L and TNPO1M697K from
TMG5, HIST1H1CK181R from TMG6, and SUN2P117S
and HIST1H1CD72G from TMG7. Patient 4097 (332
mutations) had 3 of 24 fragments with recognition of
autologous tumor and CD4+ T cell reactivity (53%, 74%
and 81% 41BB+) to mutated HIST1H1BA71D peptide.
These fragments had 11% cumulative CD4+41BB+
T cells when co-cultured with mutated DEF6L319Q,
GAKV534M and FLOT14-11del peptides. A fourth frag-
ment had 6% CD4+41BB+ T cells in response to
mutated INPP5KL176V peptide.
Conclusions
In summary, mutation-specific T cell responses were
found in 3 of 4 patients with metastatic ovarian cancer,
which opens the opportunity to use these cells for adop-
tive T cell treatment of advanced ovarian cancer.
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